Synchrony Financial (SYF)

Synchrony Financial is trading near the lower part of its 52-week range, with the stock at $72.02 and below its 50-day and 200-day moving averages ($74.22 and $73.49). The main question for holders is whether the company's strong earnings and cheap valuation can outweigh shrinking revenue and a weak trend. Earnings have beaten estimates in each of the last seven reports, yet the stock has fallen 4.01% over the past week and 9.31% over three months. Analysts remain positive on the name, with 14 of 23 rating it buy and a median 12-month target of $88.00, but the price action has not yet followed.

Synchrony has beaten EPS estimates in all seven of the last reports, most recently on October 20, 2026, when adjusted EPS of $2.68 beat the $2.40 estimate by 11.67%. The share price rose 1.02% in the first session after that report. Yet the stock has not kept that momentum: it is 18.87% below its 52-week high and down 3.22% over one year. Only one of the seven beats was followed by a lower price in the first session, which shows that the market reacts to results but has not treated them as a lasting re-rating.

At a trailing P/E of 7.52, the stock trades at a discount to peers against a sector median of 16.5, which is 54.4% below that median. On price-to-sales, the stock is at 1.56 against a sector median of 3.8. Reported earnings per share over the last 12 months are $9.58, and the dividend yield is 1.78%. A low multiple like this usually reflects doubts about the durability of earnings, and the revenue trend is where those doubts sit.

Revenue shrank 4.70% in the latest quarter compared with the same quarter a year earlier, while the sector median grew 11.7%. Analysts expect revenue to grow only 1.2% this fiscal year, to about $15.2 billion. Profitability is strong, with a net margin of 23.40%, an operating margin of 49.84% and a return on equity of 19.83%, above the sector median of 13.8%. The question for investors is whether that profitability can hold if the top line keeps shrinking.

Insiders sold $53.6 million of stock over the last 18 months across 34 sales, against one open-market purchase worth $887. Sales of this kind are often planned in advance or made to cover tax on vesting shares, so they carry less weight than a purchase. On the analyst side, 14 of 23 rate the stock buy and 9 hold, with none at sell. Evercore ISI downgraded it to In-Line from Outperform on October 21, 2026, while Barclays kept its Overweight rating the same day.

The base case is that Synchrony trades in a range between its 52-week low and its nearby moving averages while the market waits for evidence that revenue can return to growth. For the stock to regain its footing, the price would need to close above the 200-day average and hold there, with the 50-day average turning up toward the 200-day. Revenue growth is the sticking point: the latest quarter shrank 4.70% year on year, against a sector median of 11.7% growth. If revenue stabilises and EPS keeps beating estimates, the analysts' median target of $88.00 remains the reference point. A weaker outcome would see the price test the 52-week low of $63.08, especially if further analyst downgrades follow the one from Evercore ISI on October 21, 2026. Analysts expect EPS to grow 9.7% in the next fiscal year, which is the key figure to watch.

Support sits at the 52-week low of $63.08, the nearest floor below the price and the level a further decline would meet first. Resistance begins at the 200-day simple moving average of $73.49, which is the first hurdle above the price, followed closely by the 20-day exponential moving average of $73.96 and the 50-day simple moving average of $74.22. These three averages sit within about a dollar of each other, so they form a single resistance band rather than three separate barriers. The 52-week high of $88.77 is the next level above, and a move there would require a sustained change in the trend.